MTNB - Matinas Biopharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

70.4M

Cash

24.86M

Avg Qtr Burn

-4.622M

Short % of Float

0.67%

Insider Ownership

2.92%

Institutional Own.

12.77%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MAT2203 (oral and non-toxic encochleated form of amphotericin B (CAmB)) Details Meningitis, Cryptococcal meningitis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.